Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
|
The following article is a part of conference coverage from the American College of Cardiology’s 71st Annual Scientific Session & Expo being held in Washington, DC, from April 2 to 4, 2022. The team at Cardiology Advisor will be reporting on the latest news and research conducted by clinicians and scientists in the field. Check back for more from the ACC 2022 . |
In patients who received heart transplantation, donor-transmitted lipid burden, as evaluated by near-infrared spectroscopy-intravascular ultrasound (NIRS-IVUS), decreased and was not associated with plaque progression within 12 months following surgery. These findings were presented at the American College of Cardiology 71st Annual Scientific Session & Expo, from April 2nd through 4th, in Washington, DC.
The investigators sought to evaluate the relationship between donor-transmitted lipid burden and plaque progression in the early posttransplant period. Utilizing data from a prospectively maintained database, they analyzed serial 3-vessel NIRS-IVUS imaging at the 2-month and the 12-month posttransplantation follow-up. In 22 coronary arteries, they assessed the relationship between volumetric IVUS parameters and the extent of lipid burden, which was defined as the 4-mm-long segment with the maximum lipid-core burden index (maxLCBI4mm) on NIRS.
A total of 10 patients were enrolled in the study. Participants were mean aged 45±10 years. Overall, 40% of the patients had dyslipidemia prior to heart transplantation and 100% of patients were being treated with a statin.
Results of the study showed that the percent plaque volume (plaque volume/vessel volume) exhibited a significant increase (median, 16% [IQR, 15%-17%] vs 18% [IQR, 16%-21%]; P =.009). In contrast, maxLCBI4mm decreased significantly from 2 months to 12 months following heart transplantation (136 [IQR, 53-272] vs 46 [IQR, 0-167]; P =.005). Further, maxLCBI4mm at the 2-month follow-up was not significantly associated with the increment in percent plaque burden in the early posttransplantation period (P =.089).
“Donor-transmitted lipid burden assessed by NIRS-IVUS decreased and was not associated with plaque progression within 12-months post-transplantation,” the investigators noted.
Disclosure: None of the study authors has declared affiliations with biotech, pharmaceutical, and/or device companies.
Reference
Shiraki T. The relationship between donor-transmitted lipid burden and plaque progression in patients after heart transplantation. Presented at: American College of Cardiology 71st Annual Scientific Session & Expo; April 2-4, 2022; Washington, DC.
|
Visit Cardiology Advisor’s conference section for complete coverage of ACC 2022. |
